Key opinion leaders in the fields of cardiology and diabetes discussing the need for novel therapies and how bromodomain inhibition may be the answer is not a dog and pony show. The only ones speaking were clinicians, academic researchers and Resverlogix's Ewelina Kulikowski.
They tweeted a couple times this morning from the ESC Congress. Most likely we will see a blog post or news release with a conference summary in the near future. Conference runs through Wednesday, so I wouldn't expect an update until after the conference concludes and the team is back in town.
